Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Guglietta, Silvia ^a   Chiavelli, Andrea ^a   Zagato, Elena ^a   Krieg, Carsten ^b   Gandini, Sara ^a   Ravenda, Paola Simona ^a   Bazolli, Barbara ^a   Lu, Bao ^c   Penna, Giuseppe ^a   Rescigno, Maria ^a,d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; COMPLEMENT C3A RECEPTOR; COMPLEMENT RECEPTOR; LOW MOLECULAR WEIGHT HEPARIN;

BIOMARKER; BLOOD; CANCER; CELLS AND CELL COMPONENTS; COAGULATION; DIGESTIVE SYSTEM; PHENOTYPE; TUMOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CARCINOGENESIS; CELL ACTIVATION; COHORT ANALYSIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTRACELLULAR TRAP; FEMALE; HUMAN; INTESTINE CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NEUTROPHIL; NEUTROPHILIA; NONHUMAN; PHENOTYPE; POLARIZATION; SMALL INTESTINAL TUMORIGENESIS; UPREGULATION; VERY ELDERLY; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; COLON POLYPOSIS; COMPLEMENT ALTERNATIVE PATHWAY; DISEASE COURSE; DRUG EFFECTS; GENETICS; HEMATOPOIESIS; HEMOSTASIS; IMMUNOLOGY; INTESTINE TUMOR; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SMALL INTESTINE;

ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOOD COAGULATION; CARCINOGENESIS; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE PROGRESSION; EXTRACELLULAR TRAPS; HEMATOPOIESIS; HEMOSTASIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPHILS; PHENOTYPE; RECEPTORS, COMPLEMENT;

EID: 84961705099     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11037     Document Type: Article

References (69)

1. Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., Lyman, G. H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110, 2339-2346 (2007).
2. Varki, A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110, 1723-1729 (2007).
3. Khorana, A. A., Francis, C. W., Culakova, E., Lyman, G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104, 2822-2829 (2005).
4. Donnellan, E., Kevane, B., Bird, B. R., Ainle, F. N. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr. Oncol. 21, 134-143 (2014).
5. Boccaccio, C. et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434, 396-400 (2005).
6. Shao, B. et al. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood 118, 4015-4023 (2011).
7. Turpin, B. et al. Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res. 74, 3020-3030 (2014).
8. van den Berg, Y. W., Osanto, S., Reitsma, P. H., Versteeg, H. H. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119, 924-932 (2012).
9. Gil-Bernabe, A. M., Lucotti, S., Muschel, R. J. Coagulation and metastasis: what does the experimental literature tell us? Br. J. Haematol. 162, 433-441 (2013).
10. Agnelli, G. et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 10, 943-949 (2009).
11. Agnelli, G. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N. Engl. J. Med. 366, 601-609 (2012).
12. Sionov, R. V., Fridlender, Z. G., Granot, Z. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. 8, 125-158 (2014).
13. Pekarek, L. A., Starr, B. A., Toledano, A. Y., Schreiber, H. Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181, 435-440 (1995).
14. Midorikawa, Y., Yamashita, T., Sendo, F. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res. 50, 6243-6247 (1990).
15. Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16, 183-194 (2009).
16. Granot, Z. et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20, 300-314 (2011).
17. von Bruhl, M. L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 209, 819-835 (2012).
18. Demers, M. et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl Acad. Sci. USA 109, 13076-13081 (2012).
19. Fuchs, T. A., Kremer Hovinga, J. A., Schatzberg, D., Wagner, D. D., Lammle, B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 120, 1157-1164 (2012).
20. Cappell, M. S. From colonic polyps to colon cancer: pathophysiology, clinical presentation, and diagnosis. Clin. Lab. Med. 25, 135-177 (2005).
21. Wei, H. et al. A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc(min/\+) mice. Thromb. Haemost. 111, 1121-1132 (2014).
22. Coletta, P. L. et al. Lymphodepletion in the ApcMin/\+ mouse model of intestinal tumorigenesis. Blood 103, 1050-1058 (2004).
23. Baltgalvis, K. A. et al. Interleukin-6 and cachexia in ApcMin/\+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393-R401 (2008).
24. Mishalian, I. et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol. Immunother. 62, 1745-1756 (2013).
25. Qian, Z., Chen, L., Fernald, A. A., Williams, B. O., Le Beau, M. M. A critical role for Apc in hematopoietic stem and progenitor cell survival. J. Exp. Med. 205, 2163-2175 (2008).
26. Fodde, R., Smits, R., Clevers, H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55-67 (2001).
27. Sagiv, J. Y. et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 10, 562-573 (2015).
28. Borregaard, N. Neutrophils, from marrow to microbes. Immunity 33, 657-670 (2010).
29. Mantovani, A., Cassatella, M. A., Costantini, C., Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519-531 (2011).
30. Munder, M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 158, 638-651 (2009).
31. Niers, T. M. et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit. Rev. Oncol. Hematol. 61, 195-207 (2007).
32. Zacharski, L. R., Ornstein, D. L., Mamourian, A. C. Low-molecular-weight heparin and cancer. Semin. Thromb. Hemost. 26(Suppl 1): 69-77 (2000).
33. Wang, L., Brown, J. R., Varki, A., Esko, J. D. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of Land P-selectins. J. Clin. Invest. 110, 127-136 (2002).
34. Lee, A. Y. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J. Clin. Oncol. 27, 4895-4901 (2009).
35. Zezos, P. et al. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Aliment. Pharmacol. Ther. 23, 1443-1453 (2006).
36. Schulman, S. et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J. Thromb. Haemost. 13, 1010-1018 (2015).
37. Esmon, C. T. Interactions between the innate immune and blood coagulation systems. Trends Immunol. 25, 536-542 (2004).
38. Markiewski, M. M., Nilsson, B., Ekdahl, K. N., Mollnes, T. E., Lambris, J. D. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28, 184-192 (2007).
39. Girardi, G., Redecha, P., Salmon, J. E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10, 1222-1226 (2004).
40. Puppa, M. J. et al. Gut barrier dysfunction in the Apc(Min/\+) mouse model of colon cancer cachexia. Biochim. Biophys. Acta 1812, 1601-1606 (2011).
41. Oppermann, M., Gotze, O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 82, 516-521 (1994).
42. Martin, U. et al. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J. Exp. Med. 186, 199-207 (1997).
43. Kiafard, Z. et al. Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in tubular epithelial cells of human, murine and rat kidneys. Immunobiology 212, 129-139 (2007).
44. Fuchs, T. A. et al. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176, 231-241 (2007).
45. Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl Acad. Sci. USA 107, 15880-15885 (2010).
46. Berger-Achituv, S. et al. A proposed role for neutrophil extracellular traps in cancer immunoediting. Front. Immunol. 4, 48 (2013).
47. Cools-Lartigue, J. et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. 123, 3446-3458 (2013).
48. Lin, A. M. et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187, 490-500 (2011).
49. Vossen, C. Y., Hoffmeister, M., Chang-Claude, J. C., Rosendaal, F. R., Brenner, H. Clotting factor gene polymorphisms and colorectal cancer risk. J. Clin. Oncol. 29, 1722-1727 (2011).
50. Palumbo, J. S., Degen, J. L. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb. Res. 120(Suppl 2): S22-S28 (2007).
51. Liu, Y. et al. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res. 71, 6492-6502 (2011).
52. Darcy, C. J. et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit. Care 18, R163 (2014).
53. Hellum, M. et al. Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock. Thromb. Res. 133, 507-514 (2014).
54. Brandau, S. et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89, 311-317 (2011).
55. Grabon, W., Mielczarek-Puta, M., Chrzanowska, A., Baranczyk-Kuzma, A. L-arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer. Clin. Biochem. 42, 353-357 (2009).
56. Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559-563 (2014).
57. Zhu, W. et al. Thrombin induces endothelial arginase through AP-1 activation. Am. J. Physiol. Cell Physiol. 298, C952-C960 (2010).
58. Alcalay, A. et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J. Clin. Oncol. 24, 1112-1118 (2006).
59. Haselkorn, T., Whittemore, A. S., Lilienfeld, D. E. Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control 16, 781-787 (2005).
60. Luan, Z. G., Naranpurev, M., Ma, X. C. Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation 37, 924-932 (2014).
61. Ning, C. et al. Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1beta/IL-17A axis. Mucosal Immunol. 8, 1275-1284 (2015).
62. Morigi, M. et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 187, 172-180 (2011).
63. Amara, U. et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185, 5628-5636 (2010).
64. Wu, M. C. et al. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl Acad. Sci. USA 110, 9439-9444 (2013).
65. Massberg, S. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med. 16, 887-896 (2010).
66. Yipp, B. G. et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat. Med. 18, 1386-1393 (2012).
67. Landsem, A. et al. The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood. Clin. Exp. Immunol. 182, 81-89 (2015).
68. Zhao, J., Aguilar, G., Palencia, S., Newton, E., Abo, A. rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin. Cancer Res. 15, 208-216 (2009).
69. Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. National Cancer Institute 106, dju124 (2014).